Blue Horseshoe Stocks: Momentum Mover & More

True 2 Beauty, Inc. TRTB

TRTB is a momentum play that caught our attention when it began to break out during yesterday’s session. The characteristics of this high-flyer have us on alert for the possibility of continued upward movement, and a subsequent dip-and-rip situation. The stock has a low float, and as we know, that type of structure can give way to surges in buying pressure such as those that are fed by heavy momentum.

This stock virtually exploded yesterday, so it’s going to be very interesting to see how trading action resumes today. With such rapid movement, it wouldn’t be surprising to see significant bounce opportunities once it pulls back from these monstrous initial gains and begins to rebound.

Side Note: TRTB was actually tied to another stock that has appeared in our reports, APDN. Last month the two companies announced a collaboration agreement to develop a DNA-based authentication solution (Read Joint PR)  A quick tag search for APDN on our blog shows that we began tracking this stock years ago, going all the way back to the summer of 2012 when the stock was trading below .10. The company just completed an uplisting to the NASDAQ, and is currently trading in the 2.70-range.


Direxion Daily Jr Gld Mnrs Bull 3X ETF (JNUG)

We’ve been continuously tracking JNUG for several weeks now; on Tuesday, after tagging the play in our extended watchlist, we witnessed a 15% increase from 5.29-6.09.

Yesterday brought forth a consolidation to a morning low of 4.83, and a subsequent intraday snap-back to 5.80 (+20%) and then continued to consolidate into the close, and this morning it appears to be gapping up above the $5-mark.

We’ll be keeping a close eye on JNUG moving forward; despite the dollar being at 5-year highs, supply and demand still play a large role in gold price action, and from October-January with the Indian Celebration of Diwali and Chinese New Year coming up, demand for gold will be pushed to high levels.


Extended Watchlist:
NVAX, MAGS, ANV, IAG, RPI

Blue Horseshoe Stocks: Revisiting PSID


PositiveID Corp. PSID

We’ve got a lengthy history with this morning’s topic of discussion, PSID, which dates all the way back to 2013. Early this year, we tracked this play over an impressive range from .0572 to .125 over a short time period in late February to early March. That move gave us the chance to bag gains close to 120%

Recently, the chart has shown some rapid swings in the .03-.085 range, and after coming down to find support at .034 last week the stock is beginning to look like it’s in a good position to bounce again, but before we break down the PSID chart let’s recap what the company does.

For those who might not remember, PSID has hung its hat on a couple of key products:

M-BAND - PSID’s M-BAND Detector, in a nutshell, is a bio-aerosol device that uses cell lysis and nucleic acid purification to provide continuous analysis of air quality. The M-BAND screens for bacteria, viruses, and other bio-toxins.This pathogen detector has already been tested in the field. The company recently shipped several units to Maryland for continued testing to protect U.S. warfighters as part of The Joint United States Forces Korea Portal and Integrated Threat Recognition (JUPITR) program >>> Read PR


Firefly Dx -
This is PSID’s point-of-care diagnostic tool still under development. It’s a portable handheld device capable of sample lysis, purification, PCR analysis in the field. The ultimate goal is to provide point-of-care diagnostics in 20 minutes or less with a device that could essentially fit in your pocket. Due to the nature of PSID‘s products, it’s not a surprise that the recent Ebola scare drove this stock to spike violently last month.  In the time since then, we’ve learned that the company is working with U.S. Special Operations Command in hopes of continuing the development of the Firefly Dx system and bringing it into the realm of real-world use. >>> Read PR

TODAY’S NEWS:

This morning the company released both Quarterly and 9-Month financials, the highlights of which included reported revenue of $325,000 for the quarter ended 09/30/14, and $745,000 for the 9 months ended 09/30/14.  PSID also increased its 2014/2015 revenue and backlog estimate to $3.6 million, and reiterated its revenue guidance of $4-10 million through the end of 2015 (2014 and 2015 combined) >> Read PR

CHART:

As we said earlier regarding the PSID chart, we can see a lot of potential in its current positioning. It’s coming off of support, with the RSI approaching the 50-line and a MACD that appears to be ready to undergo a bullish cross. We want to have PSID at the top of our watchlists as it has shown us its ability to make rapid gains on multiple occasions. Go ahead and check out the video presentation we prepared on the PSID chart below:

More Info @ PositiveIDcorp.com

Blue Horseshoe Stocks: ZAZA Update & More

ZaZa Energy Corp. ZAZA

We tagged ZAZA last Thursday on the heels of an earnings beat, and at the time, we mentioned that we’d put the stock on watch for a classic dip-and-rip scenario.

While it took more than a full session for it to settle back and find support, it did so on Friday, bouncing off of the 2.87-mark. Yesterday ZAZA continued to trend off of that bottom and reached a subsequent high of 3.60. For us, that marks a three-day turnaround on ZAZA with possible gains of up to 25%

In order for us to remain interested in ZAZA, we’ll need to see support hold at or above the 50DMA of 3.24.



Geron Corp. GERN

We also want to make mention of GERN, which we put on watch Friday after the company announced it had licensed its cancer treatment to a unit of Johnson & Johnson in a contract that could reportedly be worth up to $935 million.

After seeing a low of 2.72 from GERN initially on Friday, the stock began to rebound up to yesterday’s high of 3.10. (+14%) and appears to be gapping up slightly in the premarket today.

Folks might be interested in tuning in to the live webcast of GERN presenting at the Stifel 2014 Healthcare Conference in New York,  NY today at 1:50 p.m. EST. Webcast link can be found at GERN’s Website, HERE >>>


Gainers From Yesterday’s Watchlist

NV5 Holdings, Inc. NVEE
NVEE made a decent move during yesterday’s session, trading in a positive range from 10.60-12.40, offering up the chance for a 19% intraday gain.

Amicus Therapeutics, Inc. FOLD
Another modest yet notable mover came in the form of FOLD, which increased from a low of 6.22 and reached 7.10, a move of 14%


Extended Watchlist:
JNUG, AUY, DNDN, UEC, ONVO

Blue Horseshoe Stocks: FCGD Update & More

First Columbia Gold Corp. FCGD

We wanted to take an opportunity this morning to update our subscribers on the recent activity of FCGD. In the weeks since we published our initial report on October 30th, the stock has provided us with a couple of quality swing trade opportunities.

The first came the week before last, as the stock traded in a range from .075-.095, a gain of 26% After pulling back to find support at .07 this past Tuesday, FCGD made another push, reaching as high as .11 on Friday. That added another 57% swing, and brought our cumulative total of possible gains on FCGD over the course of just a couple of weeks to 73%

The good news is, the chart is still looking as if it’s gearing up for the next run, as we pointed out below:

Also, don’t forget, First Columbia is involved in an expanding oil & gas project in Kentucky, and is actually pulling resources from the ground. Their current ten-well program was nearly halfway to completion as of the latest PR update from FCGD, so we’re going to be waiting intently for further information regarding the project.

Another good way to establish a clear picture of the company’s progress and operations would be to listen to the exclusive interview we conducted with FCGD CEO Jason Castenir via our sister site, Stock Traders Talk. >>> CEO INTERVIEW

More Info on FCGD @ FirstColombiaGold.com
or connect with FCGD on Facebook, Twitter and YouTube


Solar3D, Inc. SLTD

We also want to make mention of SLTD; the stock came down to a low of .18 on Friday and immediately began to recover ground, so this is one we’ll enter into the log as a possible bottom-bouncer.

Provided it can hold support at or above the current 50DMA at .19, we’ll have it on watch to possibly continue to rebound as we begin a new trading week.


Extended Watchlist:
FOLD, ABGB, CADC, NSPH, MSTX, NVEE

Blue Horseshoe Stocks: IMSC Update & More

Implant Sciences Corp. IMSC

We caught IMSC earlier this week on Tuesday, as it popped up on a routine news scan that morning; the company had announced a potentially lucrative contract with the TSA and the stock was gapping up pretty big.

It took a couple of sessions for the stock to come down and find support, and yesterday following an update on the TSA contract in which we learned that the initial order for over 1100 explosive detectors to be deployed in airports across the country was received, the stock began to run. >> Read PR

From an early low of 1.26 IMSC made a nice 22% intraday move, topping out at 1.54. We want to continue to pay attention to this play as the week comes to a close, in the wake of this morning’s Q1 2015 earnings release, which contains some favorable figures:



Off of Today’s News Scan

We’ll group our Extended Watchlist items together with links to the important PR’s each of the companies has out this morning.

Armco Metals Holdings, Inc. AMCO released earnings which beat expectations: ARMCO METALS HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report (Fri 8:32AM EST)

Geron Corp. GERN licensed its cancer treatment to a unit of Johnson & Johnson for up to $935 million: Geron could get $935M in blood disorder drug deal (Thu, Nov 13)

SkyPeople Fruit Juice, Inc. SPU announced vastly increased Q3 revs:SkyPeople Q3 Revenue Up 79% to $34.8 Million, Net Income Increases 45% to $4.7 Million (Fri 6:00AM EST)


Blonder Tongue Laboratories, Inc. BDR
also released earnings today: BLONDER TONGUE LABORATORIES INC Files SEC form 10-Q, Quarterly Report (Fri 8:31AM EST)

Immunocellular Therapeutics, Inc. IMUC announced continued favorable results from trials of their dendritic cell-based immunotherapeutic vaccine: ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncology Annual Meeting 2014 (Fri 6:00AM EST)